Physician profile
Susannah E Donahue-Negbaur
NPI 1225062953
$700.06
in general payments reported to CMS, 2019-2025
15 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Obstetric, Inpatient provider received nationally (typical 2025 total: $94.16).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $153 · 2022: $129 · 2023: $97.97 · 2024: $153 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $417.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $118.22 | 2021-2025 | Injectafer |
| Evofem Biosciences, INC. | $88.61 | 2021-2024 | |
| Abbvie INC. | $83.55 | 2021-2022 | |
| Biogen, INC. | $79.65 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $69.44 | 2022-2023 | Slynd |
| Sumitomo Pharma America, INC. | $66.69 | 2023-2024 | Myfembree |
| Coopersurgical, INC. | $51.10 | 2024 | Paragard T 380a |
| Myovant Sciences INC. | $24.70 | 2022 | |
| Astellas Pharma US INC | $19.75 | 2024 | Veozah |
| Mayne Pharma Commercial LLC | $18.41 | 2025 | |
| Shield Therapeutics INC | $17.63 | 2025 | |
| Organon LLC | $17.45 | 2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $15.88 | 2022 | |
| Avion Pharmaceuticals | $15.68 | 2021 | |
| Pfizer INC. | $13.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susannah Donahue-Negbaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.